Serum Biomarkers for Early Detection of Gynecologic Cancers
Open Access
Abstract
Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.Keywords
This publication has 83 references indexed in Scilit:
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control StudyJNCI: Journal of the National Cancer Institute, 2010
- Serum amyloid ACancer, 2009
- Identification of potential serum markers for endometrial cancer using protein expression profilingJournal of Cancer Research and Clinical Oncology, 2009
- HE4 as a biomarker for ovarian and endometrial cancer managementExpert Review of Molecular Diagnostics, 2009
- Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerBritish Journal of Cancer, 2009
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusGynecologic Oncology, 2008
- Multiple tumour marker assays in advanced cervical cancer: Relationship to chemotherapy response and clinical outcomeEuropean Journal of Cancer, 1996
- Immunosuppressive Acidic Protein (IAP) and Squamous Cell Carcinoma Antigen (SCC) in Patients with Cervical CancerGynecologic Oncology, 1994
- Immunosuppressive Acidic Protein and CA 125 Levels in Patients with Ovarian CancerOncology, 1991
- Immunosuppressive acidic protein in patients with ovarian cancerCancer, 1983